Research Article
Impact of Temporomandibular Joint Pain in Rheumatoid Arthritis
Table 1
Demographic and background data for 33 patients with temporomandibular joint (TMJ) involvement of rheumatoid arthritis.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
% abn: percentage of observations with positive or abnormal values (when applicable), n: number of observations, M: males, F: females, IU: international units, NSAID: nonsteroidal anti-inflammatory drug, DMARD: disease-modifying antirheumatic drug, anti-TNF: biologic drug specifically targeting tumor necrosis factor. The following values were considered abnormal: rheumatoid factor >14 IU, C-reactive protein >4 mg/L, erythrocyte sedimentation rate >20 mm/h, thrombocyte particle count >300 × 109/L, and ACPA >5 U/mL. The disease activity score for 28 joints was assessed at the time of clinical examination. |